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“I HATED EVERY MINUTE OF TRAINING, 
BUT I SAID ‘DON’T QUIT’. SUFFER NOW 
AND LIVE THE REST OF YOUR LIFE AS A 
CHAMPION” 























Although immense progress has been made in the fields of chemo- and radiotherapy during the 
last decades, surgery is still the ultimate cure for the majority of patients with colorectal cancer. 
Since colorectal cancer most often presents at a high age and in patients often suffering from a 
large burden of comorbidity, it is important to develop strategies to improve postoperative 
recovery and outcome, not only for the patient, but also from a health economic perspective. 
ERAS (Enhanced Recovery After Surgery) is an evidence-based concept aiming to reduce 
surgical stress, shown to reduce perioperative morbidity, improve postoperative recovery and 
shorten length of stay (LOS). Today, the international ERAS® Society Interactive Audit System 
(EIAS) includes a database containing more than 80 000 patients, each patient with more than 
300 perioperative variables recorded. The database is a valuable source for research and a guide 
for surgical centres to sustain and improve principles of perioperative care. 
Within the research field of ERAS, our research group identified two major questions that need 
further investigation. First, single interventions included in the ERAS protocol require further 
evaluation regarding the impact on the protocol as a whole. Second, most studies have so far 
been focusing on short-term outcomes after surgery. The effect of an ERAS-program on long-
term outcome is however, largely unknown. 
The overall aim of this thesis was to investigate these topics and hopefully fill some of the 
knowledge gaps concerning these questions. 
In paper I we evaluated the effect of perioperative fluid management on short-term 
postoperative outcomes and 5-year survival after surgery. This single-center cohort study 
included patients with colorectal cancer operated between 2002 to 2007. In all, 911 patients 
were enrolled. Patients receiving < 3000 mL iv fluid on the day of surgery were compared with 
patients receiving > 3000 mL. A restrictive fluid management was associated with shorter LOS 
(mean 5.6 vs 9.0 days, p < 0.001), lower risk of complications (odds ratio (OR) 0.44, 95 % 
confidence interval (CI) (0.28 – 0.71)) and symptoms delaying discharge (OR 0.47, 95 % CI 
(0.32 - 0.70)). The risk of cancer specific death was significantly reduced (hazard ratio (HR) 
0.45, 95 % CI (0.25 – 0.81)). The study concluded a possible association between a restrictive 
fluid regimen and improved short- and long-term outcomes. 
In paper II the aim was to compare robotic and laparoscopic rectal tumor surgery within an 
ERAS setting regarding short-term outcomes and compliance to the ERAS protocol. This 
single-center cohort study included 47 patients operated with laparoscopic technique between 
January 2011 to April 2014 and 72 patients operated with robotic technique between April 
2014 to January 2017. Robotic surgery was associated with shorter LOS (median 3 vs 7 days, 
p < 0.001), lower rate of complications (25 % vs 49 %, p < 0.01) and a lower conversion rate 
to open surgery (11 % vs 34 %, p = 0.002). Results endured in multivariate analysis. 
Compliance to the ERAS protocol showed no difference between groups. The conclusion, in 
this single-center cohort study, was that robotic rectal tumor surgery demonstrated superior 
short-term outcomes compared to laparoscopic rectal tumor surgery. 
In paper III the Swedish part of the international ERAS database was used to compare short-
term outcome in patients operated on with robotic, laparoscopic and open rectal tumor surgery. 
Compliance to the ERAS® Society Guidelines was compared between groups. This multi-
center retrospective cohort study included 3125 patients between January 2010 to February 
2020. Robotic surgery showed similar complication rates compared to open surgery (35.9 % 
vs 40.9 %, OR 1.15, 95% CI (0.93, 1.41)) and laparoscopic surgery (35.9 % vs 31.2 %, OR 
0.88, 95% CI (0.71, 1.08)). LOS was shorter in the robotic group, median 6 days vs 9 days in 
the open group (incidence rate ratio (IRR) 1.35, 95% CI (1.27, 1.44)) and 7 days in the 
laparoscopic group (IRR 1.14, 95% CI (1.07, 1.21)). Robotic surgery had a lower conversion 
rate compared to laparoscopic surgery (8.3 % vs 18.0 %, OR 2.58, 95 % CI (1.85, 3.60)). Pre- 
and intraoperative compliance to the ERAS protocol were similar between groups. In 
conclusion, this multi-center cohort study demonstrated shorter LOS in robotic surgery vs open 
and laparoscopic surgery and lower conversion rate to open surgery in the robotic group vs the 
laparoscopic group. 
In paper IV the aim was to identify predictors for anastomotic leakage (AL) in patients 
operated with anterior resection (AR) included in the Swedish part of the international ERAS 
database. Altogether 1900 patients were investigated between January 2010 to February 2020, 
155 patients with AL and 1745 patients without AL. Obesity (OR 1.71, 95 % CI (1.04, 2.80)), 
male gender (OR 1.88, 95 % CI (1.28, 2.75)), duration of primary surgery (OR 1.13, 95 % CI 
(1.02, 1.24)), peritoneal contamination (OR 1.78, 95 % CI (1.01, 3.16)) and surgery late in the 
study period (OR 1.89, 95 % CI (1.18, 3.01)) were all independent predictors for AL. Patients 
suffering from AL had longer LOS (median 7 vs 15 days, p < 0.001) and higher rate of 
reoperations (69.7 % vs 6.6 %, p <0.001) compared to patients without AL. No difference in 
pre- and intraoperative compliance was seen between groups. In conclusion, this multi-center 
cohort study showed that male gender, obesity, duration of surgery, surgery late in the study 
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Colorectal cancer is the third most common form of cancer worldwide, second only to lung and 
breast cancer, accounting for approximately 1.8 million new cases per year. About 0.9 million 
people die from the disease each year, making colorectal cancer the second most common cause 
of cancer-related death in the world today1, 2. Western Europe, Australia and New Zeeland show 
the highest incidence, compared to a low incidence in Africa1. 
Colorectal cancer is mostly a disease appearing at high age, with only about 5 % of the cases 
presenting before the age of 403. Median age at diagnosis, for colorectal cancer overall, is 70 
years4. Rectal cancer accounts for 35 % of all colorectal cancer incidence. Globally, the incidence 
of right-sided colon cancer is increasing5, 6 and there are data describing an increased incidence 




Adenocarcinoma of the colon and rectum is thought to have its origin from an existing 
preneoplastic adenoma9-11. The development from a benign adenoma to a malignant tumor 
probably take many years and involves several mutations in the mucosal DNA. This accumulation 
of mutations, ultimately resulting in malignant transformation, is called the adenoma-carcinoma 
sequence, a theory that was published in 199012. The prevalence of colonic adenomas in the U.S. 
population older than 50 years is estimated to 20-53 % and adenocarcinoma 0.2-0.6 %, suggesting 
that most adenomas are static or even regress with time. Risk for developing cancer or high-grade 
dysplasia is related to the size of the adenoma, where adenomas larger than 10 mm are considered 
more prone to malignant transformation10, 13. 
Age is probably the most important risk factor for developing colorectal cancer14, but as for most 
other forms of malignancy, there is no known single triggering factor for the disease. However, 
environmental, inflammatory and hereditary factors all seem to play a part in the development. 
Well known environmental risk factors are smoking15-17, alcohol18, 19 and overweight20. 
Publications have demonstrated a correlation between red meat and colorectal cancer21. Physical 
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activity, fruits and vegetables might have a protective effect22-25, while diabetes increases the risk 
of developing colorectal cancer. This might explain part of the association between obesity and 
colorectal cancer, since diabetes is overrepresented in obese people26. Patients suffering from 
long-standing ulcerative colitis27 and Mb Crohn28 are at increased risk of developing colorectal 
malignancy29. Furthermore, data on association between the gut bacterial microbiome and 
colorectal cancer is emerging where E.Coli and Fusobacterium in increased quantity are seen as 
potential risk factors in developing cancer in the colon and rectum30, 31. 
In most cases (70-80 %) colorectal cancer appears as sporadic disease. Hereditary factors cause 
or affect up to 20-30 %, but only in 2-8 % of the cases a single gene is found as the triggering 
factor for the disease. In these patients, which are identified by investigating potential family 
history of the disease, the tumor is caused by germline mutations, correlated with a high risk for 
malignant development32-34. 
The most common hereditary syndromes are Lynch syndrome and Familial adenomatous 
polyposis (FAP). Lynch syndrome is estimated to account for about 3 % of colorectal cancer 
cases and is caused by germline mutations in mismatch repairgenes35-37. These mutations give 
rise to errors in replicating repetitive DNA sequences and induce microsatellite instability38, 39. 
Endometrial cancer, ovarian and stomach tumors can appear in patients with this syndrome as 
well40. Lifetime risk of developing cancer is 70-90 %41. 
FAP is attributed to a germline mutation in the adenomatous polyposis coli (APC) gene. About 1 
% of colorectal cancer cases is caused by FAP and it will inescapably lead to cancer if left without 





Changes in otherwise stable bowel habits, anemia and blood in the stool should rise early 
suspicion of colorectal cancer, but a tumor can also remain asymptomatic until reaching an 
advanced stage. Rectal bleeding in persons older than 45 years should prompt lead to colonoscopy 
or CT colonography43. 
Colonoscopy or CT colonography are mandatory when suspecting intestinal malignancy where 
colonoscopy has the advantage of superior accuracy for small lesions and enables biopsies for 
pathology diagnosis. These investigations are also important in detecting synchronous cancers, 
existing in about 2 – 4 % of cases1, 44. With this knowledge, visualization of the entire colon 
should be completed postoperatively, if for some reason not possible before the operation. For 
rectal cancer, it is mandatory to perform rectoscopy to define the exact distance from the anal 
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verge. This is important in decision making regarding choice of surgical approach and 
neoadjuvant therapy. 
When deciding on neoadjuvant treatment, staging of the tumor is also important, especially in 
rectal cancer. In tumor staging, MRI and CT scan are preferred methods45, 46. Twenty percent of 
patients diagnosed with colorectal cancer present with distal metastasis47, most common in the 
liver, hence imaging of the liver should be done for all patients. Sensitivity of MRI is slightly 
higher than CT48. Lung metastasis appear in about 2 % of newly diagnosed colorectal cancer 
patients49. Staging should therefore also include a chest CT. 
A multidisciplinary team conference, where surgeons, radiologists, pathologists and oncologists 
discuss and recommend treatment for each patient with colorectal cancer, is today considered a 
requirement for treating patients with colorectal cancer. Assessment by multidisciplinary teams 
is associated with better outcome50-52. 
 
1.1.4 Surgical treatment 
 
Surgery is the primary treatment for colorectal cancer, since a curative resection most often is 
needed for long-term survival. For rectal cancer, TME (total mesorectal excision) removing the 
mesorectum with embedded lymph nodes, resulting in improved survival outcome, is advocated53, 
54. In colorectal cancer surgery, reliable staging requires at least 12 lymph nodes, since an 
increasing number of detected lymph nodes is considered a favourable prognostic sign4. In this 
aspect however, it is not demonstrated whether a ”hight-tie” ligation of the central blood vessel, 
i.e. a more radical extirpation of lymph drainage, is related to prolonged survival55. In addition, 
increased risk of local recurrence and distant metastasis have been demonstrated in patients with 
involved circumferential margin in rectal cancer surgery56, 57. For same reasons, CME (complete 
mesocolic excision) may be recommended in colon cancer surgery, yielding superior specimen 
and including increased number of lymph nodes58. 
 
1.1.5 Radiation therapy for rectal cancer 
 
The previous high rate of local recurrence has decreased since the introduction of TME surgery59, 
but neoadjuvant therapy still remains important. The rate of local recurrences decrease even more 
after neoadjuvant radiotherapy60, 61, 62 due to downstaging of the tumor, promoting better outcome 
after surgery, i.e. to facilitate micro- and macro radical (R0) resection. There are two principal 
treatment schedules, long-course radiotherapy (a radiation dose of 1.8 Gy per day up to 28 
fractions), or short-course radiotherapy (5 Gy x 5). 
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In Sweden, short-course radiotherapy has for many years been followed by immediate surgery, 
but recently, a 6-10 week interval, with intention to downsize the tumor, has been the first choice63 
of treatment. Long-course radiotherapy is often combined with oral fluoropyrimidine 
(Capecitabine), acting as a radio-sensitizer. When combined, studies have shown a decrease in 
local recurrence rate, but benefit in terms of increased survival rate is lacking64. Neoadjuvant 
radiotherapy is chosen over adjuvant radiotherapy since reduced rates of local recurrences and 
toxic effects have been shown comparing the two regims65. Radiation therapy for colon cancer 
has not showed any benefits in terms of either survival or local recurrence66. 
Rectal cancer can be staged in to three different groups when considering neoadjuvant therapy – 
”good”, ”bad” and ”ugly” (Table 1). Good tumors are in no need of preoperative treatment and 
can proceed to surgery alone. Bad tumors will ordinarily require short-course radiotherapy while 
ugly tumors generally will receive chemoradiotherapy67.  
 
Table 1. Rectal tumors based on radiological TNM staging67 
 Good Bad Ugly 
Low tumor (< 8 cm) T1-2, N0, MRF- T3, N1-2, MRF- T4, T3, MRF+ 
High tumor (> 8 cm) T1-T3b, N0, MRF- T3c-d, N1-2, MRF- Lateral nodes 
T – invasiveness of the primary tumor, N – lymph node status, MRF – mesorectal fascia 
 
In recent years, the concept of “watch-and-wait” has been implemented in clinical practice. This, 
since neoadjuvant radiotherapy (alone or combined with chemotherapy) has been shown to 
achieve complete clinical and radiological response in up to 20 % of localized rectal cancer cases. 
The concept includes close monitoring of patients and has so far been proven safe with 
encouraging outcomes68. 
 
1.1.6 Adjuvant chemotherapy 
 
Adjuvant chemotherapy may eliminate remaining micrometastases and thereby reduce the risk of 
overall cancer recurrence43. Cornerstones of adjuvant therapy are 5-Fluorouracil (5-FU) 
combined with leucovorin, acting as a modulator or the oral prodrug (Capecitabine) and 
Oxaliplatin. Five year survival for stage III colon cancer after surgery can reach as high as 60 %69 
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(Table 2) where survival rate is increased by 15% and recurrence rate is decreased by 17 % in 
patients treated with 5-FU based adjuvant therapy compared to no chemotherapy at all70. Several 
studies, including the MOSAIC study, have demonstrated survival benefits adding Oxaliplatin to 
5-FU/LV70-73, but a major drawback related to this drug is the increased risk of peripheral 
neuropathy74. 
 
Table 2. TNM classification75 
T – invasiveness of the primary tumor, N – lymph node status, M – metastases 
 
In stage II (node negative) cancers, surgery will usually provide cure, however up to 30 % will 
eventually develop disease recurrence76. Several studies70, 77 have shown trends toward better 
survival in individuals given adjuvant chemotherapy. Adjuvant therapy is therefore considered in 
patients with stage II disease having one or more high risk variables such as: T4 stage, perforated 
or obstructing tumor, fewer than 12 nodes analyzed, vascular or perineural invasion or emergency 
surgery14, 69, 78. 
Evidence regarding the benefit of adjuvant therapy in rectal cancer patients is however largely 
missing since results from studies on survival are conflicting79-81. Despite this, in clinical reality, 
some rectal cancers are treated similarly as colon cancers, i.e. stage III and high-risk stage II 
cancer patients without contraindications are offered adjuvant therapy. 
Adjuvant chemotherapy should start within 8 weeks after surgery to achieve optimal outcome82. 
The duration of treatment is usually six months, although data on three months treatment have 
demonstrated lower toxicity without compromising treatment efficacy83. 
  
Stage T N M 
0 Tis N0 M0 
I T1-2 N0 M0 
IIA T3 N0 M0 
IIB T4a N0 M0 
IIC T4b N0 M0 
IIIA T1-2 N1/N1c M0 
 T1 N2a M0 
IIIB T3-T4a N1/N1c M0 
 T2-T3 N2a M0 
 T1-T2 N2b M0 
IIIC T4a N2a M0 
 T3-T4a N2b M0 
 T4b N1-N2 M0 
IVA Any T Any N M1a 




1.2 SURGICAL STRESS AND PATHOPHYSIOLOGY 
 
Regulation of normoglycemia requires a balanced hepatic glucose production in addition to an 
ordered glucose uptake by tissues of the body. This balance is to a large extent maintained by 
insulin, the major anabolic hormone in humans. 
The effect of surgery can be described similar to a traumatic injury to the patient. In response to 
surgery, the body is set in a catabolic state, followed by destruction of body tissue, release of 
glucose, amino acids and fatty acids into the bloodstream, altering glucose, insulin and protein 
metabolism84, 85. Surgical trauma activates the sympathetic nervous system, as well as the 
hypothalamopituitary axis, triggering release of counter-regulatory hormones, such as 
catecholamines, cortisol, glucagon and growth hormone and cytokines (IL-1, IL-6 and tumor 
necrosis factor-alpha (TNFa)), resulting in insulin resistance and elevated blood glucose levels85. 
Reduced sensitivity to insulin in tissues of the body, i.e. insulin resistance, is regarded one of the 
main underlying factors behind the body’s destructive response to surgery86, 87. 
Although the complete mechanism behind insulin resistance and catabolism is yet to be 
discovered, insulin resistance has been described to induce release of proinflammatory cytokines, 
generate oxidative stress and have a negative effect on the immune system88-91. The skeletal 
muscle is the principle site for trauma-induced insulin resistance, since it represents the largest 
part of insulin-mediated glucose uptake. Catabolism in muscles leads to protein breakdown and 
release of amino acids used by the liver to produce glucose as energy and to generate the base for 
protein synthesis in the wound and liver92-95. 
These factors changing metabolism, ultimately result in apoptosis and cell dysfunction rendering 
worse recovery88, 91. In addition, studies have shown increased number of infections, longer length 
of stay (LOS) and even higher mortality rates in patients with an elevated blood glucose level 
after surgery96. Elevated Hemoglobin A1c, a marker for glucose control of the preceding 3 
months, has also been described as a possible risk factor for complications after surgery97, 98. 
























1.3 ENHANCED RECOVERY AFTER SURGERY (ERAS) 
 
Despite constant progress in the use of chemo- and radiotherapy, surgery is still, in most cases, 
the required treatment in patients with colorectal cancer99. Since the disease often presents at high 
age and patients often carry a large burden of comorbidity14 with an increased risk of 
complications, improved perioperative care and postoperative recovery are important, not only 
for the patient, but also from a broader health economic perspective. 
Historically, no general guidelines on how to treat patients undergoing colorectal surgery 
perioperatively have been available and perioperative care has often been dependent upon 
decisions from individual surgeons100. With the exception of nil per os and bed rest after surgery, 
which were considered standard of care, perioperative treatment varied widely between different 
centers. Furthermore, outcome recorded in databases and registers were rare entities in the past, 
making evaluation and interpretation of data on surgical outcomes difficult. Also, most data were 
retrospectively recorded by the surgeons themselves without an objective assessment of data, 
which resulted in reports on morbidity from colorectal surgery in varying rates ranging from 8 to 
75 %101-103.  
In 1994, the concept of “Fast-track surgery” was described for the first time in the literature104 
and in the late nineties Henrik Kehlet and coworkers in Denmark presented a multimodal 
interventional approach in colorectal surgery aiming to reduce surgical stress and enhance 
postoperative recovery105-107. Further publications by the Danish group showed that it was 
possible to discharge patients from hospital as soon as 48 hours after major colorectal surgery108 
compared to LOS within traditional care up to 14 days. 
These initial publications together with an increasing interest in enhanced recovery among 
surgeons and anesthesiologists across Europe lead to the foundation of the Enhanced Recovery 
After Surgery (ERAS) collaboration in 2000, which in turn led to the formation of the ERAS 
Society in 2010. The main goal with the ERAS society is to develop, spread and implement the 
ERAS protocol, improve surgical outcome and facilitate comparisons and analyzes of outcomes 
in colorectal surgery. In order to optimize this work, a common database was created109, 110. The 
ERAS Interactive Audit System (EIAS) today includes more than 80 000 patients with more than 
300 perioperative variables recorded on each patient. The database allows single hospitals to 
benchmark against other centres within the audit system, both facilitating the implementation of 
ERAS programs and supporting ERAS centers in the follow-up of their own outcome data in 
order to continuously improve results from surgery110. In research, EIAS represents an important 
source for comparing surgical techniques and study outcomes from surgery. 
Cornerstones of ERAS is evidence-based perioperative care, multidisciplinary and multi-
professional approach, teamwork and continuous recording and audit of data. ERAS care relies 
on evidence in medical research and guidelines are continuously developed and updated, stating 
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quality of evidence and recommendations using the GRADE validation system111-113. By using a 
multimodal interventional approach with the aim to reduce metabolic stress and insulin resistance, 
studies have shown reduced morbidity rates, improved recovery and shortened LOS after 
colorectal surgery114-119, when comparing ERAS to traditional care. The protocol includes 
interventions covering the whole perioperative process starting with the first meeting with the 
patient in the outpatient clinic until 30 days follow up after the operation. 
The most recent ERAS guidelines in colorectal surgery include 25 ERAS perioperative 
interventions119, which are arranged in four subgroups: preadmission, preoperative, intraoperative 
and postoperative interventions. The quality level of evidence differs between different 
interventions and to what degree each intervention contributes to an improved total perioperative 
outcome is still largely unknown120-122. This explains why the use of all interventions still is 
recommended by the ERAS society. ERAS interventions, quality of evidence and 
recommendation grade are shown in Table 3. 
Limitations in quality of research, in particular in early ERAS studies, are the majority of small 
conducted single-center based studies and a large variability in numbers of ERAS interventions 
used in various forms of ERAS protocols101, 114. Thus, by following the current protocol, with a 
predetermined number of interventions, research within the ERAS field will improve. 
Another important factor that was only sparsely reported in early ERAS publications is 
compliance to interventions in the ERAS protocol. There are now convincing evidence that 
improved compliance to the protocol improves outcomes, measured as complications, overall 
recovery and hospital stay123-125. Measuring compliance to the ERAS protocol also provides 
detailed information on perioperative care, making comparison of different surgical approaches 
and techniques suitable. Since overall improved outcomes from surgery has been shown to reduce 
costs126, 127, it is of great importance to constantly evaluate new surgical techniques. 
In previous non-ERAS studies, the association between complications, reoperations and worse 
oncological outcome are well known128-130. In ERAS studies however, the research has focused 
mainly on short-term outcomes after surgery and very few publications are reporting on ERAS 
and long-term oncological outcome data. It is important to study the ERAS protocol and long-
term outcome, since surgical stress in individuals undergoing major surgery can result in 
immunological, inflammatory, endocrine and metabolic changes involving increased levels of 
catecholamines, increased insulin resistance, elevated levels of proinflammatory cytokines and 
decreased immune response. These alterations may result in a pro-metastatic milieu causing 
increased proliferation, adhesion and migration by residual tumor cells, as well elevated number 
of complications and reoperations, leading to delay in chemotherapy and in the end worse 
oncological outcome, including increased risk of cancer recurrence131, 132. 
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The ERAS concept and laparoscopic colorectal surgery have been shown to reduce postoperative 
morbidity and LOS133, 134, although meta-analyses and randomized controlled trials (RCTs) show 
similar survival data comparing laparoscopic and open colorectal surgery135-140. 
In this context, within the research field of ERAS, at least two major questions need further 
investigation. First, single interventions in the ERAS protocol require further evaluation regarding 
the impact on the protocol as a whole. Also, current and new interventions need to be adapted to 
new surgical techniques such as robotic surgery. Second, most studies have so far been focusing 
on short-term outcomes after surgery. The effects of an ERAS-program on long-term outcome, 
most certainly needs further attention. 
The thesis will investigate this research field and hopefully fill some of the knowledge gap 





















Table 3. ERAS interventions, quality of evidence/recommendation grade119 
Preadmission Preoperative Intraoperative Postoperative 
Information M/S PONV H/S Standard anesthetic 
protocol L/S 
No gastric tubes H/S 










Nutritional care M/S No bowelprep in 









No drains H/S Limited time of 
urinary drainage H/S 
 Carbohydrate loading 
L/S 
 Prevention of ileus 
H/S 
   Glycemic control L/S 
   Nutritional care L/S 
   Early mobilization 
M/S 
Quality of evidence: high (H), moderate (M), low (L). Recommendation grade: strong (S), weak (W). Grading of 
Recommendations, Assessment, Development and Evaluation (GRADE) system. PONV = prevention of nausea 
and vomiting.   
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1.4 SELECTED ERAS INTERVENTIONS 
 
1.4.1 Preadmission information and counseling 
 
Preoperative optimization is an essential part of the ERAS protocol119. Although the evidence 
level regarding preoperative education and information is relatively low compared to other ERAS 
interventions, clinical experience indicates that this specific intervention is important in reducing 
LOS. 
Advantages due to preadmission information demonstrated in studies include improved patient 
satisfaction, reduced pain and anxiety141-143. Improved outcomes in terms of LOS due to patient 
information have also been reported in studies144, 145. 
After surgery, the criteria that need to be fulfilled for a patient to be considered ready for discharge 
in the ERAS protocol are: no complications in need of hospital stay, return of bowel function 
(stool or flatus), mobilization out of bed > 6 h daily or preoperative level and postoperative pain 
controlled with oral analgesics146. Sometimes patients are fit for discharge without being able to 
leave the hospital and an up to 2-days difference has been described109. Common causes are 
relatives’ concern, patient lacking social support and unable to handle stoma care. 
Preoperative education should begin at the first outpatient meeting and continue throughout the 
patient’s journey. Information can be given face-to-face, in writing or digital and should include 
information about tools aiding recovery and self-management, goal setting in the perioperative 
period, information about surgery, anaesthesia and discharge criteria147. 
 
1.4.2 Preoperative optimization 
 
1.4.2.1 Preoperative nutrition 
 
Preoperative malnutrition and weight loss are common in colorectal surgery148. Associations with 
increased morbidity, complication rates and worse survival are well described in the literature119, 
149, 150. It is of great importance to identify, assess and correct malnutrition as early as possible. 
Screening tools using BMI, weight loss, food intake, disease severity, age and serum albumin 
have been developed. A universal consensus on how to assess preoperative nutritional status is 
lacking, but several validated scoring systems exist – Malnutrition Universal Screening Tool 
(MUST), Nutrition Risk Screening-2002 (NRS-2002) and Subjective Global Assessment (SGA). 
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Hypoalbuminemia is considered a predictor for increased morbidity and mortality after surgery, 
but should not by itself be regarded a marker for malnutrition, since low albumin is common in 
surgical patients due to systemic inflammation151. 
Enteral nutritional supplementation starting at least one week before surgery has been 
demonstrated to reduce postoperative complication rates. Parenteral nutrition should be reserved 
for patients with contraindications to oral feeding, or patients unable to meet requirements with 
enteral nutrition149. 
 
1.4.2.2 Smoking and alcohol cessation 
 
Smoking is associated with increased mortality and morbidity rates after surgery. Complications 
include cardiovascular, respiratory, wound-healing and surgical site infections152, 153. Information 
on smoking cessation or counselling should start as early as possible before surgery to achieve 
best outcomes. Optimal duration to reverse the effects of smoking is unclear, but 4 weeks or 
longer has been shown to reduce postoperative complications154, 155. Counselling combined with 
nicotine replacement therapy are effective and increase smoking cessation rates156. 
Alcohol abuse and hazardous drinking are also known to increase postoperative morbidity and 
complication rates157. Similar to smoking cessation, 4 weeks of alcohol abstinence will reduce 
the risk of postoperative complications 158. Information and counselling, sometimes combined 
with pharmacotherapy, should be initiated as soon as possible to achieve alcohol cessation. 
Since smoking and alcohol cessation only entail positive effects for the patient, recommendations 
are strong in ERAS guidelines. 
 
1.4.3 Treatment of anemia 
 
The definition of anemia according to the World Health Organization (WHO) is a hemoglobin 
(Hb) level of < 120 g/L for women and < 130 g/L for men. In between 30 to 67 % of colorectal 
cancer patients will suffer from anemia during the course of disease159. 
In general, many factors can cause anemia, such as vitamin B12 or folate deficiency, 
chemotherapy and renal failure. In colorectal cancer patient however, the main contributors of 
anemia are chronic blood loss and anemia of chronic disease, i.e. colorectal cancer160. 
Anemia entails increased risk of complications and mortality in patients going through major 
surgery161-163. In addition, preoperative anemia is a major predictor for the need of blood 
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transfusion during surgery, a factor linked to both an increased rate of complications after surgery 
and a negative impact on long-term survival164, 165. 
Thus, it is of great importance to optimize Hb levels preoperatively. This can be achieved by 
blood transfusion, erythropoiesis-stimulating agents (ESAs) or iron supplementation. However, 
since blood transfusions should be avoided and ESAs result in increased risk for thrombosis and 
mortality166, iron supplementation, which are cost-effective and safe with a very low rate of 
serious adverse events, is the preferred choice of treatment. No negative effects on morbidity, 
mortality or cancer recurrence have been found with iron supplementation167-169. 
Many cancer patients may not respond to oral iron because of blood loss or chronic illness. It is 
also poorly tolerated due to gastrointestinal side effects. Besides having a low risk of adverse 
events, intravenous iron is more effective than oral iron in correcting Hb levels and should be the 
first treatment option in colorectal cancer patients suffering from anemia prior to surgery119. 
 
1.4.4 Bowel preparation 
 
Mechanical bowel preparation (MBP) is known to cause dehydration and electrolyte imbalance, 
leading to potentially dangerous complications, particularly in elderly patients suffering from 
comorbidities170, 171. Fluid and electrolyte imbalance in the preoperative period is suggested to 
increase the fluid requirement in patients both during surgery and in the postoperative period, a 
factor known to have a negative effect on outcome122. Furthermore, MBP is not always successful 
in cleansing the bowel and surgery with a fluid-filled colon has been associated with increased 
complication rates172. 
In the literature, there is strong evidence that MBP does not reduce surgical site infection (SSI) 
rate or anastomotic leakage (AL) compared to surgery without bowel preparation173-175. There is 
no evidence whether or not MBP should be given prior to anterior resections with a defunctioning 
stoma. Most surgeons probably prefer MBP in order to avoid a colon full of faeces proximal to 
the anastomosis. 
Data from observational studies in the U.S. have indicated that a combination of oral antibiotics 
together with systemic antibiotics and MBP reduce postoperative morbidity compared to systemic 
antibiotics and MBP or systemic antibiotics without MBP176, 177. The theory behind this concept 
is that systemic antibiotics administered prior to surgery does not affect intraluminal bacteria and 
the combination of MBP and oral antibiotics will reduce bacterial load and SSI. Although recent 
meta-analyses tend to support these findings178-180, it is important to recognize that the data does 
not support the use of MBP per se. Thus, MBP alone with systemic antibiotics has no clinical 




1.4.5 Perioperative fluid therapy 
 
Perioperative fluid overload has been shown to yield impaired anastomotic healing, tissue edema 
and delayed gastrointestinal function, as well as increased overall morbidity and mortality rates181-
185. In one study, morbidity has been shown to increase more than 30 % with every additional 
intravenous liter, compared to average distribution, administrated on the day of surgery123. On the 
other hand, receiving too small amount of fluids when fluid supply is required, will cause tissue 
hypoperfusion, generating poor outcomes due to hypoxia182, 186. Therefore, to keep an adequate 
perioperative fluid balance, is of key importance in order to improve outcome from surgery. 
In the past, preoperative over-night fasting was considered standard of care aiming to minimize 
the risk of aspiration during and after surgery. Today, using ERAS principles, fasting periods 
before surgery are reduced to 6 hours for solid food and 2 hours for clear fluids and carbohydrate 
drinks187, 188 without effect on aspiration rates188. Preoperative oral carbohydrate drinks 
administrated prior to surgery have been described to reduce insulin resistance, and improving 
preoperative well-being189 and is therefore standard treatment in the ERAS protocol. However, 
evidence in terms of improved morbidity and mortality in large clinical studies is lacking. 
A balanced intraoperative fluid therapy is used for maintaining cardiac output and tissue perfusion 
without generating salt and water overload. The treatment should be individualized and aim for 
near-zero-balance. Balanced crystalloids 1-4 ml/kg/hour during surgery will generally achieve 
this goal and weight gain more than 2.5 kg should be avoided190. 
In Goal-directed fluid therapy (GDFT), devices such as the transesophageal Doppler are used to 
administer fluid boluses to guide fluid therapy and to optimize stroke volume on the Frank-
Starling curve. Improvement in stroke volume implies need for additional boluses and less 
responsiveness suggests that maintenance fluid infusion is enough191. Earlier studies have shown 
benefits from GDFT in terms of LOS and morbidity192, but recently several publications have 
challenged these results, particularly when GDFT is used in an ERAS setting193-195. Thus, within 
ERAS protocols GDFT should be reserved for high-risk patients and/or high-risk procedures190 
only. In low-risk cases with hypotension, where fluid boluses fail to increase stroke volume, 
vasopressors are recommended196. 
The alternative to GDFT is reaching near-zero fluid balance by the use of standard 
anaesthesiological care, measuring variables such as blood loss, blood pressure, pulse, urine 
output and weight gain. This guidance has been shown to decrease the rate of postoperative 
complications if aiming at a restrictive intravenous fluid regimen compared to standard fluid 
management185 and demonstrates equal postoperative outcomes compared to GDTF181, 184, 197. 
The results has been confirmed in ERAS research , where a perioperative restrictive intravenous 
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fluid regimen is an important predictor for improved short-term outcome after colorectal 
surgery123, 125, 198. 
Patients should be motivated to eat and drink as soon as 4 hours after surgery199, facilitating 
removal of intravenous fluid administration on the day of surgery for most patients. Loss of fluid 
due to vomiting and high stoma output may however need to be replaced by intravenous fluids. 
A balanced crystalloid solution is preferable to 0.9% saline and colloids for both maintenance and 
fluid boluses. Saline is associated with hyperchloremic acidosis, a condition that could result in 
kidney failure and increased morbidity190. In the past colloids were used intraoperatively, but no 
significant advantages have been shown compared to crystalloids190, 200. Also, colloids are known 
to result in kidney failure and increased mortality201, 202. 
 
1.4.6 Prevention of postoperative ileus 
 
Postoperative ileus (POI) is a state of transient prolonged gastrointestinal recovery after surgery, 
leading to abdominal distension, pain, vomiting and patient discomfort203. POI is associated with 
increased morbidity in terms of aspiration pneumonia, malnutrition, renal failure and increased 
LOS resulting in higher health care costs204-206 and suffering for patients. Due to variations in 
definition of POI, incidence ranging from 2 to 61 % has been described205. 
Abdominal surgery entails a period of reduced gastrointestinal motility, proposed to be a part of 
the body’s response to surgical stress. This reaction can last up to 72 hours in colorectal surgery. 
Absence of gastrointestinal motility lasting longer than 3 days after laparoscopic surgery or 5 
days after open surgery meets the criteria for prolonged postoperative ileus (PPOI)207. 
Intraoperative blood loss, opioid use, male gender, stoma formation, obesity, increasing age, 
duration of surgery, previous abdominal surgery and cardiac/respiratory co-morbidity203, 208, 209 
are all described as predictors for postoperative ileus in the literature. 
A sufficient perioperative pain management is an important ERAS intervention, known to 
improve recovery210. Opioid-related side effects, such as urinary retention, nausea and respiratory 
depression, are common211 and the relationship between opioid use and POI is well described in 
the literature212. Epidural analgesia reduces the need for opioids, while in addition implementing 
an inhibitory effect on the sympathetic nervous system. Both improving gastrointestinal 
motility213. 
In addition to the importance of not overloading patients with fluids in order to improve 
perioperative gastrointestinal function, laparoscopic surgery, known to improve recovery and 




Several prokinetic agents have been evaluated with conflicting results in studies, some data 
indicating improved outcomes216, but other results showing no improvement in gastrointestinal 
motility213. Gastrografin® (Amidotrizoin acid), a radiological contrast agent, has not been found 
to significantly improve return of normal bowel function217. 
In contrary to what was previously thought, early enteral feeding has been found safe and feasible. 
One RCT demonstrated improved return of bowel function and decreased LOS when early enteral 
feeding was given218. There is no evidence of increased risk of anastomotic leakage219 by early 
feeding. Chewing gum has been regarded as prokinetic, is safe and inexpensive, but has been 
withdrawn from the ERAS protocol since new data shows no evidence of improved outcomes220. 
 
1.4.7 Minimally invasive surgical techniques 
 
1.4.7.1 Laparoscopic surgery 
 
Laparoscopic colorectal surgery was introduced in the 1990s221. Today, the technique is adopted 
worldwide, with proportions of elective colorectal resections reaching beyond 90 % and 
conversion rates less than 10 % in dedicated centres. Thus, the rate of traditional open surgery 
procedures is decreasing. 
Several reviews, meta-analyses and RCTs comparing laparoscopic versus open colorectal surgery 
show a decreased rate of complications, shorter recovery and LOS in laparoscopic surgery. In 
further detail, suggested advantages with laparoscopy are reduced ileus, earlier recovery of bowel 
function, reduced need for analgesics, fewer bleeding complications and fewer wound 
infections136, 222-224. However, despite the evidence in favour of laparoscopy, there are still 
opposing arguments, such as limited two-dimensional view within the pelvic cavity, poor 
ergonomic position, unstable instruments and long learning curve225, 226. 
In the ERAS protocol, laparoscopic surgery compared to open surgery is one of the strongest 
independent predictors for improved outcome. The technique has been investigated in prospective 
and retrospective cohorts227, but also in two large RCTs, showing superior outcomes when 
combining laparoscopy and ERAS in terms of recovery and LOS133, 134. In the LAFA trial, 
laparoscopic surgery was the only independent factor leading to improved outcome in regression 
analysis133. 
In the early days of laparoscopic colorectal practice, concerns were raised about oncological 
safety. Although several studies have strongly rebutted this136, 139, 140 in both colon and rectal 
laparoscopic surgery, two recent randomized trials failed to prove noninferiority comparing 
laparoscopy to open rectal surgery using a pathologic composite score including positive 
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circumferential margin, distal margin negativity and completeness of total mesorectal excision 
(TME)228, 229. These worrying data, did however not translate into worse survival or higher local 
recurrence rate in the 3 year follow-up of these two trials137, 138. 
The MRC CLASICC trial initially showed non-significantly elevated rates of positive 
circumferential resection margin in laparoscopic anterior resections compared to open, but this 
did not translate into worse survival. The same study also demonstrated worse survival outcomes 
in patients with colonic cancer following conversion from laparoscopic to open surgery. Since 
advanced cancer was the most common reason for conversion, this might be the most likely 
reason explaining worse survival rates, rather than conversion per se139. 
 
1.4.7.2 Robotic surgery 
 
In 2006, the first data on robotic total mesorectal excision (TME) for rectal cancer was 
published230. Robotic rectal surgery has since been widely introduced, aiming to overcome many 
of the shortcomings of traditional laparoscopy in the pelvic cavity using 3-dimensional vision, 
stable camera, endo-wristed instruments and eliminated tremor231, 232. In addition, shorter learning 
curves with the robotic platform compared to laparoscopy have been suggested233, 234. 
In 2018, Prete et al conducted a meta-analysis consisting of five RCTs confirming previously 
known data, i.e. robotic surgery is associated with longer operating time and lower rate of 
conversions233. 
Other recent meta-analyses describe similar short-term outcomes in terms of morbidity and LOS, 
with no difference considering lymph node harvest and CRM positivity 235, 236. In 2017, a 
metaanalysis by Cui et al presented lower morbidity and shorter LOS in robotic surgery237. 
Shorter LOS are also shown in metaanalyses by Li et al and Simillis et al238, 239. 
However, although data of varying quality in favor of robotic surgery exists, larger studies and 
more robust meta-analyses have had difficulties to support these findings. 
The ROLARR trial, to date the largest RCT published on this topic, revealed no differences, 
neither in the primary outcome conversion rate, nor in secondary outcomes comparing 
laparoscopic and robotic rectal surgery240. Corrigan et al conducted a follow-up on the ROLARR 
trial in 2018, adjusting for learning effects, suggesting that the equality of outcomes seen in this 
study might have been influenced by the surgeons’ learning curve241. Surgeons in the laparoscopic 
group were more experienced compared to surgeons in the robotic group. Adjusting for the 
learning effect, robotic surgery seemed to have an advantage over laparoscopic surgery in terms 




Kim et al conducted a RCT in 2018, showing similar results as the ROLARR trial. In this study 
the lymph node harvest was larger, but also the estimated blood loss in robotic surgery compared 
to laparoscopy242. 
Studies show similar overall and disease-free survival when comparing robotic and laparoscopic 
rectal surgery243, 244. Since conversion may be a proxy for difficult surgery245 known to result in 
higher complication rates and worse oncological outcome 139, 246, benefits from this aspect are yet 
to be proven in robotic surgery. 
In the literature, there is only one retrospective cohort trial comparing short-term outcome in 
laparoscopic vs robotic rectal surgery within an ERAS protocol247. The study demonstrated 
significantly lower postoperative complication rates, shorter LOS, lower conversion rates 
favoring robotic surgery and shorter operating time favoring laparoscopic surgery. 
Cost is an important issue to consider when implementing new techniques. Previous studies 
including the ROLARR trial demonstrated higher costs related to the robotic approach compared 








1.5 ANASTOMOTIC LEAKAGE 
 
The rate of anastomotic leakage (AL) ranges from 0 % to 20 % in various studies conducted over 
the years, where highest rates are seen in colorectal/coloanal procedures250, 251-253. AL is one of 
the most feared and serious complications in colorectal surgery since it contributes not only to 
postoperative morbidity, mortality and reoperations, but also increases the risk of local recurrence 
and decreased long-term survival254-256. Worse outcomes in patients suffering from AL have been 
explained by a delay until start of adjuvant chemotherapy, metachronous and inflammation-
mediated carcinogenesis or implantation of tumor cells to the anastomotic site256. 
Data from studies on AL can be difficult to interpret due to lack of a universal definition on how 
to describe and diagnose AL. First, there is variability in terminology. AL could be described as 
insufficiency, anastomotic breakdown or disruption. Terms like early or late AL also exists, 
depending on time to diagnosis from primary surgery. Second, diagnosis of AL could be based 
on clinical or radiological features, important to recognize when comparing data on AL. One of 
the most cited definitions, is the one proposed by Rahbari et al. Here AL is defined as a defect of 
the intestinal wall at the anastomotic site leading to a communication between the intra- and 
extraluminal compartment of the intestine. A three-grade scale was also invented. Grade A: no 
therapeutic interventions involved. Grade B: interventions, but no laparotomy. Grade C: 
interventions including laparotomy257. 
In addition to the difficulties in defining and diagnosing AL, there are data showing contradictory 
results for many of the proposed risk factors. Some risk factors, such as male gender, high BMI 
and distal anastomosis have been associated with AL repeatedly over time, whereas data 
concerning other proposed risk factors, such as radiotherapy and diverting stoma show diverging 
results. Thus, it is still of great importance to conduct studies to increase the knowledge on AL. 
Studies on AL within an optimized care environment such as ERAS care are lacking. 
 
1.5.1 Preoperative risk factors 
 
Gender: 
Because of the narrow pelvis in males compared to women, there are several technical difficulties 
to overcome during surgery; performing total mesorectal excision (TME), transection of the 
bowel, and constructing the rectal anastomosis. Hence, male gender has in several studies been 





Obesity can be measured as Body Mass Index (BMI, kg/m2). A high BMI, indicating obesity, has 
been shown to be a significant risk factor for AL in several studies252, 260. Obesity contributes to 
an increase of the technical difficulties described above for the male gender and obese patients 
carry a larger burden of comorbidities proposed to increase the risk of AL, such as higher ASA 
score and diabetes. 
 
Preoperative radiotherapy: 
Preoperative radiotherapy also causes damage to healthy tissue why the risk of AL after surgery 
have been suggested to increase. In terms of an increased risk for AL, studies on preoperative 
radiotherapy have shown contradictory results. Some studies show an association between 
radiotherapy and AL, whereas others do not250, 252, 253, 261, 262. 
 
Preoperative chemotherapy: 
Although the mechanism behind leakage in chemotherapy treatment is unknown, several studies 
have found a significant relationship between chemotherapy and increased AL250, 263. Bowel 
ischemia due to microembolic disease caused by chemotherapy could be one explanation. Studies 
on bevacizumab (Avastin) support this in theory264, 265, although bevacizumab is given to patients 
in a palliative situation, not in a neoadjuvant or adjuvant setting. 
 
Medications: 
The use of corticosteroids has been associated with AL266, 267 although duration and dose of 
corticosteroids vary considerably among studies. Reviewing the literature, it seems that high-
dosage (> 20 mg/day) may increase the risk of AL, but when it comes to duration of use, there 
are conflicting results on the effect of AL267. 
Since the use of perioperative opioids have been shown to impair the rate of recovery, non-
steroidal anti-inflammatory drugs (NSAIDs) have gained popularity. So far, there are conflicting 
results on a troublesome suggested association between NSAIDs and AL. Some studies state that 
NSAID treatment does not increase AL rate268, 269. However, three of the most recent meta-






Several studies report an association between malnutrition, in the literature most often estimated 
by preoperative weight loss, low BMI or low serum albumin concentrations, and AL250, 273, 274. 
The proposed mechanism is that malnutrition impairs collagen synthesis and fibroblast 
proliferation. Preoperative treatment (chemoradiotherapy) could also lead to malnutrition274. 
 
1.5.2 Intraoperative risk factors 
 
Anastomosis level: 
It is widely accepted that the risk of AL increases with a more distal anastomosis253, 263, often 
explained by poorer blood supply, technical difficulties and increased tissue tension. Firm 
mechanisms behind the reason for distal anastomosis being more prone for AL are however, to a 
large extent, unknown. 
 
Number of stapler firings: 
Number of cartridges used for rectal transection is associated with increased risk of AL. The use 
of three or more cartridges significantly increases risk for AL after AR275. Multiple firings seem 
to cause weak spots in the stapler line making the anastomosis more fragile. 
 
Tumor characteristics: 
Tumor size, as well as advance stage, are associated with increased risk of AL259, 276. This might 
be due to more difficult surgery in a narrow pelvis and worse physical status in patients with a 
more advanced tumor stage. 
 
Duration of surgery: 
Intraoperative difficulties often result in prolonged duration of surgery. The reasons could be 
adhesions, obesity, bleeding, preoperative radiotherapy or difficulties in the stapling of an 
anastomosis. Thus, duration of surgery is a risk factor for AL275. 
 
Intraoperative blood loss and transfusions: 
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Blood loss and transfusions are identified as risk factors for AL276. Whether this is explained by 
factors related to the blood loss per se or a proxy for difficult surgery/poor operative technique 
remains to be confirmed. 
 
1.5.3 Postoperative risk factors 
 
Diverting stoma: 
There is a debate on whether a diverting stoma reduces the symptoms of complications following 
AL (reduction of adverse effects of AL, such as peritonitis and septicemia), rather than preventing 
leakage per se. Some data indicates that a diverting stoma reduces the incidence of anastomotic 
leakage277, while other studies fail to confirm this association253. The most recent meta-analysis, 
including only prospective RCTs, showed a significant reduction in AL and re-operation rates in 
patients receiving defunctioning stoma278. 
 
Intestinal microbes: 
The human microbiome consists of one hundred trillion microbes. Dysbiosis among intestinal 
microbes might have a negative effect on diseases such as intestinal malignancies, Crohn’s 
disease and obesity. The intestinal flora has been proposed to influence intestinal healing and AL 
and although the mechanisms still are unclear an increasing amount of data in this research field 
is emerging. So far, Lachnospiraceae, Bacteroidaceae and Enterococcus faecalis have been 






The overall aim of the thesis was to evaluate specific ERAS interventions in relation to short- 
and long-term outcomes after colorectal surgery. 
 
2.1 PAPER I 
To evaluate a possible association between restrictive perioperative fluid management and 
improved short-term outcome, as well as 5-year survival, in patients undergoing colorectal 
surgery due to cancer within an ERAS protocol. 
 
2.2 PAPER II 
To compare perioperative data, short-term outcome and compliance to the ERAS protocol in 
patients with rectal tumor operated with robotic or laparoscopic surgery within an ERAS 
setting. 
 
2.3 PAPER III 
To compare perioperative data, compliance to the ERAS protocol and short-term outcome in 
patients with rectal tumor from a multi-center cohort, operated with robotic, laparoscopic and 
open surgery within an ERAS protocol. 
 
2.4 PAPER IV 
To identify predictors for AL and study short-term outcomes in patients with or without AL 





3 PATIENTS, MATERIAL AND METHODS 
 
Paper I-IV were approved by the regional Ethics Committee of Stockholm and conducted in 
accordance with the Declaration of Helsinki of the World Medical Association. 
Paper I-IV were reported according to criteria set out in the Strengthening the Reporting of 
Observational studies in Epidemiology (STROBE) checklist280. 
A p value < 0.05 and/or 95 % CI not including 1 was considered statistically significant. Stata 
version 12.0 and 16.0 were used for statistical analysis (StataCorp, College Station, Texas, 
United States of America). 
 
3.1 PAPER I 
 
Design 
Single-center retrospective cohort study with prospectively recorded data. 
Objective 
To study the impact of perioperative fluid therapy on short- and long-term outcome after 
colorectal surgery within an ERAS setting. 
Exposure 
The exposure variable in this study was a restrictive fluid management on the day of surgery, 
i.e. the first 24 hours. A restrictive fluid regimen was defined as < 3000 ml iv fluid 
administered. This equals the compliance threshold for colonic procedures in the ERAS 
database. The threshold for rectal procedures equals < 3500 ml. This difference for restrictive 
fluid management in colonic and rectal operations was chosen since patients operated on with 
rectal surgery often receive larger amounts of fluid due to longer operating times and more 
difficult surgery. To avoid the risk of bias in patients given excessive fluids to treat a 
complication, only day 0 of fluid treatment was included in the analysis of outcome. Surgical 
procedure was adjusted for in multivariate analysis to reduce confounding due to tumor 
location. 
Outcome 
The primary outcome was length of stay after surgery. Criteria for discharge were no 
complications requiring further hospitalization, no intravenous nutrition or fluid requirements, 
no need for intravenous analgesics and return of bowel function (stool or flatus). Secondary 
outcomes were postoperative complications, postoperative symptoms delaying discharge and 
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5-year overall survival. Symptoms delaying discharge included constipation, diarrhea, fever, 
pain, fatigue and dizziness. The follow-up time was 30 days regarding short-term outcome and 
five years for long-term survival. 
Study population 
Altogether 911 patients were included in the study. Data on intravenous fluid therapy on the 
day of surgery (day 0) were collected for 898 patients. All included patients had a colonic 
and/or rectal resection due to cancer and were consecutively recorded in the ERAS database 
between January 1, 2002 to December 31, 2007 at Ersta Hospital, Stockholm, Sweden. One 
hundred and fourteen perioperative variables including data on iv fluid therapy, LOS, 
symptoms delaying discharge, postoperative complications and 30-day mortality were 
prospectively recorded in the database. Date and cause of death were retrieved from the 
Swedish Cause of Death Registry. Data on histopathology were collected from the Swedish 
National Colorectal Cancer Registry and patient charts. 
Statistics and data analysis 
Unadjusted associations between categorical variables were analyzed with c2 test or Fisher’s 
exact test when appropriate. For continuous variables a two-tailed t test was conducted. Results 
for continuous variables were presented as mean with standard deviation (SD). Frequencies 
and percentage were displayed for categorical variables. 
Adjustment variables in multivariate analyses were sex, age, American Society of 
Anaesthesiologists (ASA) physical status classification, BMI, pathology (N0/>N1) and 
surgical procedure (colon or rectum). Multivariate regression models were performed to test 
adjusted associations between exposure and short-term outcomes. Results were shown as OR 
and 95 % CI. Cox regression was executed to assess association between exposure and five-
year survival. Results were demonstrated as HR and 95 % CI. Difference in survival with 
regard to exposure was tested using the Kaplan-Meier method and Log-rank test. 
 
3.2 PAPER II 
 
Design 
Single-center retrospective cohort study with prospectively recorded data. 
Objective 
To study and compare robotic and laparoscopic rectal tumor surgery regarding perioperative 




The exposure variable in this study was surgical approach – robotic or laparoscopic rectal tumor 
surgery which were compared over two time periods, January 2011 to April 2014 for 
laparoscopic surgery and April 2014 to January 2017 for robotic surgery. 
Outcome 
The primary outcome was length of stay after surgery and secondary outcomes were 
postoperative complications, conversion to open surgery and compliance to the ERAS 
protocol. 
Study population 
The study was carried out at Danderyd Hospital, Stockholm, Sweden and included all patients 
who had rectal surgery between 12 January 2011 to 30 January 2017. Altogether 224 patients, 
102 during the first time period and 122 during the second time period, had rectal surgery due 
to cancer or adenoma. One hundred and nineteen patients, 47 laparoscopic procedures during 
the first time period and 72 robotic procedures during the second time period were 
consecutively included in the study. All patients were consecutively and prospectively included 
in the ERAS database, recording more than 300 perioperative variables together with 21 
specific ERAS interventions. A standardized ERAS protocol was used with the aim of fulfilling 
all 21 key ERAS variables for each patient. Data on specific clinical parameters and pathology 
were retrieved from patient charts. Complications were classified according to Clavien-
Dindo281. 
Statistics and data analysis 
A power analysis calculated on an estimated difference in the primary outcome (LOS) with 80 
% power at a two-sided alpha of 0.05, resulted in a number needed to treat (NNT) estimate of 
38 patients in each group. 
Crude group comparisons between continuous variables were handled using a two-tailed t test 
or Wilcoxon’s rank sum test based on variable distribution. c2 test or Fisher’s exact test were 
used to test associations between categorical variables when appropriate.  
Adjusted associations were calculated using multiple logistic and linear regression. Adjustment 
variables in multivariate analyses were sex, age, ASA physical status classification, BMI, 
pathology (N0/>N1) and surgical procedure. Compliance data was calculated as the number of 
accomplished interventions divided with the total number of pre-, intra or postoperative 
interventions. 
 





Multi-center retrospective cohort study with prospectively recorded data. 
Objective 
To compare compliance to the ERAS protocol and short-term outcomes in patients operated 
with robotic, laparoscopic or open technique due to rectal tumor included in the Swedish part 
of the international ERAS database. 
Exposure 
The exposure variable was surgical approach, with robotic surgery as the reference group. All 
patients were analyzed according to intention-to-treat. 
Outcome 
Primary outcomes were length of stay after surgery and postoperative complications. 
Secondary outcomes were pre- and intraoperative compliance to the ERAS protocol, 
reoperations, symptoms delaying discharge (paralytic ileus, pain, diarrhea, obstipation, 
vomiting and urinary retention), duration of surgery and conversion to open surgery. All 
preparations for minimally invasive surgery were included in the operating time. 
Study population 
Validation of the Swedish part of the international ERAS database was conducted in 2019. The 
validation included missing values, data on accuracy and coverage. All units included in the 
study aimed to treat patients according to the ERAS protocol including more than 300 
perioperative variables and 24 ERAS interventions. All data was prospectively and 
consecutively recorded. All patients operated in Sweden with anterior resection or 
abdominoperineal resection (APR) in centers recording data in the international database 
between January 1, 2010 to February 27, 2020, due to rectal tumor (benign or malignant), were 
included in the study (N = 3125). Eight hundred and twenty-seven patients (26.5 %) had robotic 
surgery, 869 patients (27.8 %) had laparoscopic surgery and 1429 patients (45.7 %) were 
operated on with open approach. 
Statistics and data analysis 
Power analysis was calculated on an estimated difference in length of stay between groups and 
38 patients in each group was estimated to reach 80 % power with a two-sided alpha of 0.05. 
To compare surgical approaches regarding basic characteristics, pre- and intraoperative 
compliance, postoperative compliance and symptoms delaying discharge univariate regression 
was used. Logistic regression was used for binary variables, ordinal logistic regression for 
ordinal variables, linear regression for continuous variables with normal distribution and 
Kruskal-Wallis test for continuous variables without normal distribution.  
Multivariate regression models were then used testing adjusted associations between exposure 
and outcome. Zero-truncated negative binomial regression for LOS, logistic regression for 
complications, symptoms delaying discharge, reoperations, and conversion to open surgery and 
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linear regression for duration of surgery. Multiple imputation was used to deal with missing 
values282. Adjustment variables included in the multivariate analysis were age, gender, BMI, 
ASA physical status classification, alcohol abuse, previous surgery, preoperative 
chemoradiotherapy, severe pulmonary disease, cancer, pre- and intraoperative compliance, 
surgical procedure (AR or APR) and year of surgery (2010 – 2015 or 2016 – 2020). 
Categorical variables were given as frequencies and percentage and continuous variables as 
mean with SD or median with interquartile range. 
 
3.4 PAPER IV 
 
Design 
Multi-center retrospective cohort study with prospectively recorded data. 
Objective 
To investigate potential predictors for anastomotic leaks in patients operated with anterior 
resection due to rectal tumor within an ERAS protocol. 
Exposure 
The exposure variables were basic characteristics, intraoperative variables and pre- and 
intraoperative compliance to the ERAS protocol. All variables are listed in Table 1-3, paper 
IV. 
Outcome 
Anastomotic leakage (binary variable, defined and recorded as AL in the ERAS database, i.e. 
radiological diagnosis and/or reoperation) was primary outcome in the study. Secondary 
outcomes were LOS after surgery, death (30-day) and postoperative complications (30-day) 
regarded as potential effects of AL.  
Study population 
The study included all patients with rectal tumor (benign or malignant) operated on with AR 
and registered in the Swedish part of the international ERAS database between January 1, 2010 
to February 27, 2020. Altogether 1900 patients operated with robotic, laparoscopic or open 
technique were included in the study, 155 (8.2 %) with AL and 1745 (91.8 %) without AL. 
Data on exposure, outcome, perioperative variables and compliance to the ERAS protocol were 
collected from the database.  
Statistics and data analysis 
 
32 
With an estimated difference in leak rate of 5 % between two surgical approaches, at least 145 
patients in each group were needed to detect an OR of 2.11 with 80 % power. Unadjusted 
associations between basic characteristics, intraoperative variables, pre- and intraoperative 
compliance and AL were tested using c2 test or Fisher’s exact test. For difference in compliance 
rate, Wilcoxon’s rank sum test was performed. These tests were also used when analyzing 
univariate associations between secondary outcomes and AL. Categorical variables were 
presented as frequencies and percentage and continuous variables as mean and SD or median 
and interquartile range.  
Logistic regression was used in multivariate analysis controlling for confounders. Results from 
multivariate analysis were presented as OR and 95 % CI. Based on prior research and univariate 
associations with AL in this study we included the following variables in multiple regression 
analysis: gender, age, BMI, ASA physical status classification, surgical approach, additional 
procedure, peritoneal contamination, preoperative radiotherapy, year of surgery (2010 – 2015 
or 2016 – 2020), pre- and intraoperative compliance rate, duration of primary surgery and new 






4.1 PAPER I 
 
Nine hundred and eleven patients were included in the study. Data on intravenous fluid therapy 
on the day of surgery (day 0) were collected for 898 patients. Of the patients enrolled in the 
study, 3.1 % had laparoscopic surgery. Basic characteristics are presented in Table 4. 
 
Table 4. Basic characteristics, univariate analysis 
 Exposed group 
≤ 3000 ml (N=145) 
Unexposed group 
>3000 ml (N=753) 
p-value 
Age (Years ± SD) 69.3±12.6 69.3±11.5 0.516a 
Gender (M/F) 51/94 393/360 <0.005b 
BMI ± SD 24.8±4.3 25.4±4.3 0.957a 
ASA I (N,%) 26 (19.9) 120 (17.5)  
ASAII (N,%) 86 (65.7) 436 (63.6)  
ASAIII (N,%) 19 (14.5) 122 (17.8)  
ASAIV (N,%) 0(0) 8 (1.2) 0.452c 
Preoperative metastasis 
(N,%) 
11 (7.6) 86 (11.4) 0.172b 
Surgical procedure: 
colonic/rectal (N,%) 
121/24 (83.4) 374/379 (49.7) <0.005b 
Values in parenthesis are percentages if not stated otherwise. Basic characteristics: ASA (American Society of 





Since male gender and rectal surgery were associated with larger volume of iv fluids day 0 in 
univariate analysis, these variables were adjusted for in the multivariate analysis. When 
comparing T- and N-stadium of tumors, no difference could be detected when comparing 
exposed and unexposed groups. 
Patient with > 70 % compliance to pre- and intraoperative variables received less iv fluids day 
0 compared to patients with < 70 % compliance (mean ± SD, 3348 ± 913 mL vs 4985 ± 1501 
mL, p < 0.05).  
Univariate comparisons of selected postoperative outcomes are shown in Table 5. 
 
Table 5. Selected short- and long-term outcomes. Univariate analysis 
 Exposed group 
≤ 3000 ml (N=145) 
Unexposed group 
>3000 ml (N=753) 
p-value 
LOS, days ± SD  5.6±3.4 9.0±7.9 <0.001a 
Post-op symptoms (N,%) 61 (42.0) 455 (60.4) <0.001b 
Post-op complications (N,%) 29 (20.0) 320 (42.4) <0.001b 
Unspecified death within 5 year 
(N,%) 
31 (21.4) 247 (32.8) 0.006b 
CRC specific death within 5 year 
(N,%) 
16 (11.0) 154 (20.5) 0.008b 
CRC = colorectal cancer. aTwo-tailed t test, bPearson`s c² test. 
 
All significant differences between groups remained in multivariate analysis. The exposed 
group (< 3000 ml) had a lower rate of complications (OR 0.44, 95 % CI (0.28 – 0.71)), 
symptoms delaying discharge (OR 0.47, 95 % CI (0.32 – 0.70)) and the risk of cancer specific 
death was reduced with 55 % in Cox regression analysis (HR 0.45, 95 % CI (0.25 – 0.81)). 
Improved survival in the exposed group was demonstrated using Kaplan-Meier survival 




4.2 PAPER II 
 
In all 119 patients were included in the study, 47 had laparoscopic surgery in the first time 
period and 72 had robotic surgery in the second time period, illustrated in Figure 2. 
 
Figure 2. Flow chart study cohort. N (%) 
 
Lap = laparoscopic resection, Open = open resection, Robot = robotic resection. 
 
There was no significant difference in compliance to pre- and intraoperative interventions of 
the ERAS protocol between the two groups. Patients in the robotic group were younger (65.5 
(mean) ± 10.4 (SD) yrs vs 70.1 ± 12.0 yrs, p = 0.014), had a lower tumor height (8.5 ± 3.6 cm 
vs 9.8 ± 3.9 cm, p = 0.043) in univariate analysis, compared with patients in the laparoscopic 
group. Although a higher rate of patients in the robotic group compared to the laparoscopic 
group were treated with preoperative chemotherapy and had a higher rate of ASA class III-IV, 
these differences did not reach significance. 
Short-term outcome demonstrated shorter length of stay in the robotic group compared to the 
laparoscopic group (median 3 days vs 7 days, p < 0.001), while length of stay for patients 
operated with open technique did not differ between time periods. Overall complication rate 
was significantly lower in the robotic group (25 % vs 49 %, p < 0.001), Figure 3. The 
differences remained significant in multivariate analysis. 
All patients (N=224)
January 2011 - April 2014 (N=102) 
Lap 47 (46) Open 55 (54)
April 2014 - January 2017 (N=122) 
Robot 72 (59) Lap 15 (12) Open 35 (29)
Lap N=47 Robot N=72
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Figure 3. Complications and LOS 
 
Overall complication rates were significantly lower in the robotic group (p<0.001). The difference in more 
serious complications Clavien ≥3, was not significant (p=0.543). LOS was significantly shorter in patients 
operated on with robotic technique (p<0.001). 
 
Conversion rate to open surgery was significantly lower for the robotic technique compared to 
the laparoscopic technique (11.1 % vs 34.0 %, p = 0.002). Overall postoperative compliance 
measures, regarded as outcome variables after surgery such as time to pain control, hours out 
of bed on the first postoperative day, time to tolerate solid food, time to withdrawal of urinary 
catheter and time to flatus demonstrated significantly better results in the robotic group. 
 
4.3 PAPER III 
 
Taken together 3125 patients were included in the study, 45.7 % (N = 1429) had open surgery, 
27.8 % (N = 869) had laparoscopic surgery and 26.5 % (N = 827) had robotic surgery. Surgical 
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Figure 4. Surgical approach stratified by time 
 
From the year 2015, the rate of open procedures decreased steadily. No robotic procedures were performed 
before 2013 and the proportion was increasing with time, c2(14) = 753.54, p < 0.001. 
 
Univariate analysis comparing basic characteristics showed higher rates of cancer diagnosis 
(97.4 % vs 95.4 %, p = 0.012), abdominoperineal resections (40.6 % vs 36.3 %, p = 0.043) and 
additional procedures (11.1 % vs 5.4 %, p <0.001) in the open group compared to robotic group. 
Previous surgery to the abdomen was more common in the open surgery compared to robotic 
surgery (27.0 % vs 22.7 %, p = 0.020). 
Pre- and intraoperative compliance to the ERAS protocol was similar between groups, although 
a small, yet significant, difference was shown comparing the laparoscopic and robotic groups 
(93.8 % vs 92.6 %, cohen’s d =0.16, p = 0.001). Analyzing postoperative compliance, regarded 
as outcome measures, minimally invasive surgery showed superior results in every aspect, 
compared to open surgery. Variables analysed were total IV volume of fluids day 0 (mL), time 
to passage of flatus (days), first passage of stool (days), time to tolerating solid food (days), 
termination of urinary drainage (days) and time to pain control with oral analgesics (days). 
In multivariate analysis, adjusting for confounding, robotic surgery showed shorter length of 
stay compared to both laparoscopic surgery (IRR 1.14, 95 % CI (1.07, 1.21)) and open surgery 
(IRR 1.35, 95 % CI (1.27, 1.44)). LOS (median) was 6 days, 7 days and 9 days for robotic, 
laparoscopic and open surgery respectively. Conversion to open surgery was more common in 
the laparoscopic group (18.0 % vs 8.3 %, OR 2.58, 95 % CI (1.85, 3.60)) compared to the 
robotic group but the duration of surgery was longer in the robotic group, mean 5.77 hours 
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compared to both laparoscopic surgery, mean 5.49 hours (linear coefficient -0.05, 95 % CI (-
0.08, -0.01)) and open technique, mean 4.84 hours (linear coefficient -0.21, 95 % CI (-0.24, -
0.17)). Univariate analysis on selected complications are illustrated in Figure 5. The overall 
complication rate and number of reoperations did not differ between groups in adjusted 
analysis. Symptoms delaying discharge were more common in open surgery compared to 
robotic surgery in multivariate analysis (OR 1.62, 95 % CI (1.29, 2.04)). 
 
Figure 5. Selected complications (%) stratified by surgical approach 
 
✭ P value < 0.05 was considered being significant based on Bonferroni adjustment. 
In univariate analysis, the rate of deep wound dehiscence (1.8 % vs 0.4 %), urinary tract injury (1.7 % vs 0.6 %), 
pneumonia (4,0 % vs 1.2 %) and wound infection (15.1 % vs 8.0%) was significantly higher in open compared to 
robotic surgery. Anastomotic leaks however, had a significantly lower rate (4.3% vs 7.1%). 
Except from a significantly higher rate of postoperative bleeding in the laparoscopic group (1% vs 0.1%) compared 
to the robotic group no other differences were found. 
Further, 14 different types of complications were compared (not shown) without significant difference between 
groups with the exception of a significantly higher rate of cardiac arrythmia in the open compared with the robotic 
group. 
 
4.4 PAPER IV 
 
In total, 1900 patients were included in the study. The rate of anastomotic leakage was 8.2 % 
(N = 155). Figure 6 illustrates AL rate over time stratified on surgical technique. Surgery late 
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in the study period (2016 – 2020) was a risk factor for AL in both uni- and multivariate analysis 
(9.8 % vs 5.1 %, OR 1.89, 95 % CI (1.18, 3.01)) compared to surgery early in the study period 
(2010 – 2015). Surgical approach was not a predictor for AL. 
 
Figure 6. Anastomotic leakage over time stratified by surgical approach 
 
In multivariate analysis male gender (OR 1.88, 95 % CI (1.28, 2.75)), obesity (OR 1.71, 95% 
CI (1.04, 2.80)), peritoneal soiling (OR 1.78, 95 % CI (1.01, 3.16)) and duration of primary 
surgery (OR 1.13, 95 % CI (1.02, 1.24)) were all significant predictors for AL. 
Overall compliance to pre- and intraoperative ERAS interventions showed no significant 
difference comparing AL and no AL groups (OR 0.99, 95 % CI (0.97, 1.01)). AL group 
demonstrated worse overall postoperative compliance (outcome) measures (data not shown). 
Secondary outcomes showed worse result for patients with AL regarding major complications 
(63.9 % vs 5.9 %, p <0.001), reoperations (69.7 % vs 6.6 %, c2 (1) = 542.68, p <0.001) and 






Figure 7. Selected complications (%) stratified by presence of AL 
 
* P value less than 0.05 was considered significant. Further 12 complications were compared (not shown) 
without significant difference between groups. 
 

















5.1 PERIOPERATIVE FLUID THERAPY 
 
In paper I, a single-center cohort study investigating volumes of administered perioperative 
fluids and outcome from surgery, the major findings were an association between a restrictive 
intravenous fluid regimen on the day of surgery and a decrease in length of stay after surgery, 
postoperative complications and symptoms delaying discharge, as well as an improved 5-year 
cancer specific survival. 
In ERAS protocols, shown to reduce surgical stress and improving postoperative recovery114, 
118, 119, the use of a balanced or a restrictive perioperative fluid regimen have been shown to be 
an important independent variable for outcome123, 125, 198. 
During surgery, iv fluids can be administered either by the use of standard anaesthesiological 
care reaching a near-zero balance or by adopting the concept of goal directed fluid therapy 
(GDFT), using fluid boluses and devices such as the esophageal doppler to measure the need 
for fluids. The opinion on whether to use GDFT or not differs among studies192, 194 and in the 
latest ERAS guidelines119 the recommendation is that GDFT should be reserved for high-risk 
patients and high-risk procedures only. To reach a near-zero fluid balance using standard 
anaesthesiological care will thus be enough for most patients. In paper 1, GDFT was not used 
on any of the patients included in the study. This might, to a certain degree, contribute to the 
fairly large range (700 – 12900 mL) of iv fluid administered in this cohort. 
In previous studies, data have shown worse short-term outcomes both when applying a liberal 
fluid management, as well as inducing hypovolemia123, 181-186. However, the definition of what 
is a liberal vs a restrictive or balanced fluid management varies, which makes it difficult to 
draw firm conclusions of an optimal perioperative fluid management. In our study, a restrictive 
fluid management on the day of surgery, was defined as < 3000 mL of iv fluid administered 
day 0 in both colonic and rectal procedures. In the ERAS database however, the definition of 
a restrictive, or compliant, fluid regimen differs between colonic (< 3000 mL) and rectal (< 
3500 mL) procedures. All outcome data was therefore adjusted for surgical procedure in the 
multivariate analysis in order to avoid confounding caused by differences in iv fluid given 
between procedures and the fact that bowel preparation is more common in rectal surgery. 
Perioperative bleeding did not differ between colonic and rectal surgery in our cohort, a factor 
that otherwise could have had impact on the amount of fluid administered. Whether it is the 
threshold for fluid administration set in the ERAS protocol, or in the present study that is correct 




Considering the relatively long inclusion time (2002 – 2007) in this observational study, there 
is a possibility that a more “liberal” fluid regimen was used early in the study period compared 
to a more “restrictive” regimen in the late period. In 2002, standard of care was still a more 
“liberal” fluid regimen and to adopt ERAS principles with a more “restrictive” fluid treatment 
probably took several years. This time variable together with a large rate of open surgery (96.9 
%), might explain the poor compliance rate (21.0 %) to the treatment of iv fluids day 0 in the 
present study.  
In study I, all patients were treated according to a standardized ERAS protocol, including 21 
perioperative interventions, at the time of inclusion. Compliance to the protocol interventions 
is divided into pre-, intra- and postoperative measures. Pre- and intraoperative compliance to 
ERAS interventions, such as preadmission counselling, use of premedication and oral intake 
day 0, are to a large extent independent from patient factors affecting outcome and thus 
included in compliance analysis. Compliance to postoperative interventions, such as time to 
solid food intake, time to pain control and mobilization, i.e. outcome measures from surgery, 
were not included in overall compliance analysis, due to possible impact from surgical 
outcome. In study I, patients with > 70 % compliance to pre- and intraoperative interventions 
received less iv fluid compared to patients with less than 70 % compliance, indicating that 
although the results were adjusted for confounding, a small difference in pre- and intraoperative 
interventions other than fluids may have had an effect on outcome. 
Results presented in this study, i.e. superior short-term outcome and improved 5-year survival 
in patients receiving < 3000 mL iv fluid day 0 is in line with previous publications showing 
that increased adherence will result in improved outcomes after surgery123, 125, 198. The 
mechanisms by which ERAS protocols might have a positive effect on long-term oncological 
outcome are so far speculative. Theories include surgical trauma stimulating dormant 
remaining cancer cells or post-operative influence on the immune response131, 132, 283-285. 
Overall complications were reduced with restrictive fluid management in the present study, 
which is consistent with results from earlier studies on long-term follow-up that have shown 
postoperative complications to be associated with worse survival286, 287. 
 
5.2 MINIMALLY INVASIVE SURGERY 
 
In paper II and III, different surgical approaches used within an ERAS setting were compared 
regarding compliance to the protocol and short-term outcomes. In Paper II, a single-center 
cohort study, comparing laparoscopic and robotic rectal tumor surgery between two time 
periods, the results showed a significantly shorter LOS, reduced complication rates and fewer 
conversions to open surgery in the robotic group. In Paper III, a multi-center retrospective 
cohort study of patients from all centers in Sweden recording in the International ERAS 
database was conducted. To our knowledge the largest observational publication comparing 
short-term outcome in patients undergoing robotic, laparoscopic or open rectal tumor surgery. 
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The results showed significantly shorter LOS in the robotic surgery group compared to 
laparoscopic and open surgery and lower conversion rate to open surgery in robotic vs 
laparoscopic surgery. Complication rates did not differ between groups in Paper III. Pre- and 
intraoperative compliance to the ERAS protocol was similar between groups in both studies. 
Despite the fact that laparoscopic colorectal surgery was introduced 30 years ago221 it has taken 
a long time to show benefits compared with traditional open surgery. Today however, summing 
up the level of evidence, laparoscopy show superior short-term outcomes223, 224 and similar 
long-term oncological outcomes137, 138, 222-224 compared to open surgery. 
The first publication on robotic TME was published in 2006230, since then many studies have 
been conducted, many of them underpowered and often of poor quality. Furthermore, no 
studies have investigated robotic surgery in an optimized perioperative environment, such as 
ERAS care. 
Survival rates seem to be similar between robotic and laparoscopic rectal surgery243, 244. When 
comparing short-term outcomes, the most recent meta-analysis consisting of small RCTs, 
confirmed previously published results, i.e. robotic surgery is associated with longer operating 
time and lower rate of conversion to open surgery233. There are however, several meta-analyses 
showing improved short-term outcomes for robotic surgery237-239, but these are often hampered 
by small sample sizes and low quality evidence. The ROLARR trial, to date the largest RCT 
published on this topic, revealed no differences in primary outcome – conversion rate, or 
secondary outcomes comparing laparoscopic and robotic rectal surgery240. However, a recent 
follow-up study suggested that the results shown in the ROLARR trial might have been 
influenced by the surgeons’ learning curve, since surgeons in the laparoscopic group were more 
experienced than surgeons in the robotic group241. 
Similar superior short-term outcomes in favour of robotic surgery shown in paper II have been 
repeated in a recently published retrospective cohort trial within an ERAS setting247. Outcomes 
with such a great advantage for robotic surgery might to some extent be explained by bias and 
confounding due to the single center study design. The large difference in LOS between robotic 
and laparoscopic surgery in paper II could, to a certain extent, depend on better postoperative 
compliance and a lower conversion rate to open surgery but also the fact that single coworkers 
in the medical staff may have had an impact on the results that cannot be adjusted for. In this 
context, it is important to notice that median LOS in open surgery did not differ between the 
two time periods. The lower complication rate in robotic surgery compared to laparoscopic 
surgery in paper II may be biased by the same factors as in the difference in LOS, but the fact 
remains that robotic surgery had lower mean CRP values in the postoperative period, which 
indicates decreased intraoperative tissue damage. Overall, despite the risk factors for bias when 
analyzing results, it is of great value to know what a single-center institution can achieve, when 
implementing new minimally invasive techniques in an ERAS environment. 
Paper III was conducted in order to investigate if the results on robotic surgery in a limited 
single center environment could be confirmed with a large sample size from a nationwide 
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multicenter database. The results from paper III showed better outcomes for robotic surgery 
compared to laparoscopic surgery in terms of LOS and conversion rate, when these two 
minimalinvasive techniques were compared in relation to open surgery. When comparing 
robotic surgery with open surgery, all postoperative compliance measures were better in robotic 
surgery, explaining part of the difference in LOS in favor for the new surgical technique. 
However, only one postoperative compliance item, time to pain control, showed better results 
in robotic vs laparoscopic surgery. Since symptoms delaying discharge and complication rates 
were similar in both robotic and laparoscopic surgery, pain is the only factor that can explain 
the difference in LOS between the two groups. Superior visualization and exposure in a narrow 
pelvis may explain some of the difference seen in conversion rate to open surgery between 
robotic and laparoscopic techniques shown in papers II and III, however, potential benefits in 
short- and long-term due to this lower conversion rate are yet to be proven139, 223, 246. 
The longer operating time shown in robotic surgery, compared to both open and laparoscopic 
surgery, is not surprising, since adopting a new surgical technique takes time and includes a 
learning curve for all members of the team. It is important to notice that docking and set up in 
robotic surgery might explain some of the difference and that studies have shown a shorter 
learning curve in robotic surgery compared to laparoscopic surgery234, 288. The difference seen 
in operating time can be expected to decrease even further in the future. 
 
5.3 ANASTOMOTIC LEAKAGE 
 
In paper IV, a multi-center retrospective cohort study, with data from all Swedish centers 
recording in the international ERAS database, to our knowledge the first study investigating 
risk factors for anastomotic leakage in patients within an ERAS protocol, we found male 
gender, surgery late in the study period, obesity, peritoneal contamination and duration of 
surgery to be independent predictors for AL. Compared to patients with no AL patients with 
AL showed worse short-term outcome in length of stay, reoperations and overall complication 
rates. Overall pre- and intraoperative compliance to the ERAS protocol showed no difference 
comparing AL and non-AL patients. 
It has previously been shown that short-term outcomes, including morbidity, mortality and 
reoperations, as well as long-term outcomes, measured as local recurrence rate and long-term 
survival are worse in patients suffering from AL254, 287, 289 compared to patients without AL. 
However, when reviewing the literature on independent risk factors for AL, results are 
diverging250, 252, 253, where the difference in study design and sample sizes between different 
studies might to a certain extent explain the results pointing in different directions. A factor 
that further complicates interpretation of data, is the lack of consensus on how to define AL 
since there is a vast variability in terminology, grading terms and whether an anastomotic leak 
should be defined as a clinical or radiological diagnosis. The EIAS database however, provides 
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a clear definition of AL and all centers included in the current study are recording AL according 
to the same terms. 
In accordance with the results from our study, male gender is a previously well-known risk 
factor for AL. Reasons for higher leak rates in males could be surgical difficulties due to a 
narrow pelvis or hormone-related differences impeding bowel arterial circulation259, 290, 291. In 
the same way a larger burden of comorbidities and more difficult surgery can contribute to 
higher AL rates in obese patients250, 252, 253. Intraoperative contamination has been associated 
with AL in previous studies292. Peritoneal soiling during surgery could be a sign of more 
difficult surgery, a factor known to result in higher AL rates. Also, the infection itself has been 
shown to affect the anastomosis, leading to AL258. Since studies show that the leak rate tend to 
be stable over time251, 293, the association between AL and surgery late in our study period is 
difficult to explain. Registration of AL and a more accurate diagnosis, using more x-ray 
investigations, most certainly have improved over time and are factors that might explain part 
of this association. Longer duration of surgery as a risk factor for AL in the current study, is 
recognized in previous studies252, 253. Obesity, adverse events during surgery and increased 
bacterial exposure may contribute to this association. 
Previously presented risk factors, such as smoking/alcohol, diabetes, high ASA grade and poor 
nutritional status, could not be identified as independent predictors in the present study250, 274, 
294, 295. Looking into the numbers in detail, the fact that few patients in the cohort were smokers 
or had an alcohol abuse may only explain why this risk factor could not be identified as an 
independent predictor, but for the others the cause is unclear. 
Age as a borderline significant protective variable against AL, shown in the current study, is 
somewhat surprising, since there are studies with results pointing in the opposite direction250. 
Due to the observational design of this study, we cannot exclude the possibility of selection 
bias, i.e. choosing healthier older patients for AR instead of permanent stoma formation. It is 
also possible that younger patients in this cohort might have had a more advanced stage of the 
disease, leading to more difficult surgery and higher AL rates, compared to the elderly. 
Since increased compliance to the ERAS protocol has been shown to improve outcome from 
colorectal surgery, one could expect that compliance would be associated with AL as well. This 
association however, was not found in the current study. Only one intervention – excess of IV 
fluid administered intraoperatively – turned out to as a significant univariate predictor for AL, 
however not significant after adjustment for confounding. As expected, postoperative 






The greatest strength in all four studies included in this thesis is that all perioperative variables 
that were collected for analysis had been recorded consecutively and prospectively by an 
independent observer into the international ERAS database, EIAS. Coverage, accuracy and rate 
of missing values of the data in the Swedish part of the database have recently been validated, 
preliminary with excellent results. Paper III and IV in this thesis are examples of multicenter 
studies that the ERAS society are planning for in future where large sample sizes with a high 
rate of coverage of a large part of a national healthcare system enables detection of data 
reflecting clinical reality. Although paper I and II are single center studies with smaller sample 
sizes, the data have been recorded and collected in two Swedish ERAS centers of excellence 
with well-known high rate of coverage and accuracy of data as well as excellent results after 
surgery.  
In all four papers, overall rates of pre- and intraoperative compliance to the ERAS protocol 
were high and similar between the comparison groups, i.e. all patients had the same treatment 
before surgery. This provides equality in perioperative comparisons, reducing bias, making 
robust comparisons of outcomes feasible, which are considered as a major strength in all four 
studies. The observational design of all the studies included in this thesis facilitates the 
investigation of multiple covariates and outcomes. Since more than 300 perioperative variables 
are prospectively and consecutively recorded in the database considerably more factors can be 
considered compared to the gold standard study design, randomized controlled trials, that may 
not always reflect clinical reality. 
The benefits of the access to multiple data can be exemplified by the process of analyzing 
associations between perioperative fluids and outcome in paper I. Since the database contains 
information not only on the total amount of administered fluids but also the volumes of given 
fluids in every step of the perioperative process, we could analyze the amount of iv fluid 
administered on the day of surgery separately to avoid confounding. This, since the amount of 
fluids administered after surgery, may be an effect of a complication during or after surgery. In 
multivariate analyses, we could then make stepwise adjustments for a large number of 
variables, including pathology and performed surgical procedure during the perioperative 
process. Thus, the effect of potential bias from variables such as bowel preparation, potential 
differences in perioperative bleeding and iv fluid administration between colonic and rectal 
procedures could be reduced. In paper I and II, the turnover of staff and changes in the ERAS 




Despite all the advantages with large retrospective cohort studies including valid data from an 
international database, there are many well-known pitfalls with this type of study design. In 
order to avoid bias, stepwise multivariate regression models were used, but should be 
performed carefully since this method may as well introduce bias in the results. To a certain 
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degree, compared to randomized controlled studies, bias is always present to a larger extent in 
retrospective cohort studies. 
Furthermore, in all papers in this thesis, there is a risk of selection bias, since there was no 
randomization of patients when comparing groups regarding compliance to the ERAS protocol 
and outcome from surgery. Although the risk of information bias might have been reduced by 
the fact that trained ERAS nurses performed the perioperative ERAS care and that the 
recording of data into the ERAS database was performed by an independent medical staff 
worker, one can never exclude such bias confounding the results.  
Another drawback with the general use of a retrospective study design in this thesis is that it is 
impossible to draw firm conclusions about causal relationships. The data will provide evidence 
of associations, not explanatory mechanisms. 
As previously discussed only pre- and intraoperative compliance were included in analysis on 
compliance to ERAS interventions. However, this has been a calculated strategy since the 
variables that sorts under postoperative compliance are affected by the outcome on the day of 
surgery and should be looked upon as outcome variables. This can be seen as a weakness when 
analyzing the ERAS protocol, but we find it the only way to interpret data correctly. 
Although, we tried to minimize bias and confounding in all four studies using multivariate 
analysis, to the best of our knowledge and with help from statisticians, there are variables that 
are difficult to fully correct for. In observational studies, time is one example of such a factor. 
Since we reached inclusion times up to 10 years in the studies, many circumstances could have 
changed during the time period. The general attitudes among staff towards the ERAS protocol 
as a whole, but also towards different ERAS items such as iv fluid management, preop 
carbohydrate drink and different surgical procedures may have changed over time, thereby 
effecting the results in a way that is difficult to measure.  The same applies to hospital staff 
turnover and technical progress in general. In study III and IV we included time of surgery in 
multivariate regression analyses aiming to exclude the impact of time as much as possible. 
The single-center design used in paper I and II is in many ways troublesome, since it reduces 
external validity, thereby making conclusions on a broader population more difficult. There are 
a lot of environmental factors that are unique, and which differ between different surgical 
centers and since these factors are difficult to measure, the impact is unknown. In paper III and 
IV however, a multi-center design was used to reduce the risk of this type of bias.  
Finally, cost is an important issue to consider when implementing new surgical techniques. The 
fact that a cost analysis was not conducted in paper III is to be considered as a major limitation 








A restrictive compared to a non-restrictive intravenous fluid management (< 3000 mL vs > 
3000mL) on the day of surgery was associated with improved short-term postoperative 
outcomes as well as improved colorectal cancer specific 5-year survival in patients with 
colorectal cancer operated within an ERAS protocol. 
 
Paper II 
In a single-center setting within an ERAS protocol, robotic rectal tumor surgery is associated 
with shorter LOS, lower complication rates and lower conversion rate to open surgery 
compared to laparoscopic rectal tumor surgery. 
 
Paper III 
In a multi-center setting within an ERAS protocol robotic rectal tumor surgery was associated 
with shorter LOS compared to laparoscopic and open surgery. Robotic surgery showed lower 
conversion rate to open surgery compared to laparoscopic surgery. Complication rates were 
similar between all groups. Overall, outcome measures were better in minimally invasive 
surgery compared to open surgery. 
 
Paper IV 
Male gender, obesity, surgery late in the study period, peritoneal contamination and duration 
of surgery were found as independent predictors for anastomotic leakage in a multi-center 





7 FUTURE PERSPECTIVES 
 
ERAS programs are evidence-based concepts, known to reduce postoperative morbidity, 
enhance recovery and shorten length of stay after surgery. Today, the ERAS protocol includes 
25 ERAS interventions aiming to reduce the rate of surgical stress. So far, there are however 
only evidence for the implementation ERAS protocol as a whole in order to improve outcome. 
The contribution of each individual intervention within the protocol is still largely unknown. 
Although increased compliance to all interventions have been shown to improve results from 
surgery, only a few elements - minimally invasive surgery, a balanced intravenous fluid therapy 
and in some studies the preoperative carbohydrate drink have been convincingly shown as 
independent predictors of improved outcome. Since there are strong evidence for the use of all 
the interventions when studied individually, outside the ERAS protocol, there is a need for 
further research to investigate the rate of impact of each intervention when used together in the 
ERAS program. There is no point in using as many interventions as possible, rather than to 
make the protocol user-friendly and to optimize the outcome. 
Research on ERAS until today, has mainly been focused on short-term outcomes after surgery. 
There are very few reports on long-term oncological outcome. The theory behind the ERAS 
protocol in reducing surgical stress and as a possible consequence, via improved immune 
response, counteracting residual tumor cells and hereby reducing recurrence risk is appealing. 
In a few single-center studies, an association between compliance to the ERAS protocol, 
restrictive iv fluid management and increased colorectal cancer specific 5-year survival has 
been found. More studies are warranted and of special interest in this context is the role of 
minimally invasive surgery which in a very near future will dominate all surgery. So far, only 
a few studies have shown survival benefits in minimally invasive compared to open surgery, 
but these results have not been confirmed in meta-analyses and RCTs.  
In general, long-term oncological survival is the most important outcome for patients with 
colorectal cancer and it is of great importance to further clarify the complex association 
between risk factors before surgery, choice of surgical method, and the optimization of 
perioperative interventions in relation to long-term oncological outcome. 
One of many strengths of using the ERAS database in studies, is the prospective and 
consecutive recording of more than 300 perioperative variables including compliance to the 
protocol on each patient enrolled in the database. These parameters make research on exposures 
and outcomes reflecting clinical reality suitable, in a way that may not be possible in 
randomized controlled studies. In order to optimize the use of the database, it is important to 
continue the validation of EIAS in all countries included in the ERAS collaboration. After a 
complete validation, we can use the full potential of the international ERAS database, today 
including more than 80 000 patients, in designing multi-center studies with a power that by far 
exceeds most of the clinical studies conducted in the colorectal research history. 
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Globally, a major challenge for ERAS is the implementation of the protocol in developing 
countries around the world. ERAS has been shown to improve outcome and reduce costs in 
high-income countries and would be expected to do so, even in low-income countries. Since 
developing countries often struggle with both higher morbidity and mortality rates compared 
to high-income countries, the effect of implementing ERAS could have an even larger effect 
on outcome and costs in this part of the world. If such an implementation process will require 
a modification of existing protocols and guidelines or not, remains to be investigated in 
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